Rentschler Biopharma signed a license agreement with Horizon Discovery to use Horizon’s CHOSOURCE™ platform in combination with Rentschler’s in-house process for cell line development for difficult-to-express proteins. Horizon’s gene-edited Glutamine Synthetase (GS) knockout CHO K1 cGMP-compliant cell line will complement Rentschler’s existing service to support researchers from early drug development through commercial manufacturing, according to Frank Mathias, CEO of Rentschler.
“At Rentschler Biopharma, we consistently strive to offer our clients optimal and truly integrated solutions across the entire value chain,” he said. “We achieve this by our own means as well as through strong partnerships. The new collaboration with Horizon, a very renowned company in the area of cell line engineering with an outstanding track record, significantly broadens our fit-for-purpose approach.”
“This agreement brings together two world-class companies in biomanufacturing and further supports our ethos of enabling access to the CHOSOURCE platform in such a way as to empower organizations of all sizes to drive efficiencies in development and production of biotherapeutics,” added Terry Pizzie, CEO of Horizon Discovery.